Moharam Saad Ahmed, Elshikh Amgad, Abdelbadie Mohamed, Ibrahim Ahmed Mohamed, Shaheen Mostafa Mohamed Khedr, ElSharkawy Mohammed Said
Anesthesiology, Surgical Intensive Care and Pain Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Anesthesiology, Surgical ICU and Pain Management, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
Pain Rep. 2024 Oct 14;9(6):e1206. doi: 10.1097/PR9.0000000000001206. eCollection 2024 Dec.
The inappropriate management of pain after thoracotomy results in serious complications. Several adjuvants have been added to the thoracic paravertebral block (TPVB) to enhance its effects. This work aimed to evaluate the effect of adding ketamine to TPVB on thoracotomy-related acute and chronic pain.
This randomized controlled double-blinded trial included 60 patients scheduled for open thoracotomy. Patients were equally randomized into 2 groups: group K: received TPVB + 1 mL ketamine (50 mg). Group C (n = 30): received TPVB (19 mL of 0.5% levobupivacaine + 1 mL normal saline) as a control arm.
Group K exhibited a significant delay in requesting analgesia, required less morphine in the first 24 and 48 hours, and reported lower numerical rating scale at rest and at deep breathing at various time points compared with the control group. However, both groups were comparable in post-thoracotomy pain syndrome and the incidence of complications at 2 months and 3 months.
Adding ketamine to TPVB resulted in better analgesia as demonstrated by significantly delayed time to first rescue analgesia, lower total amount of consumed opioid, and pain score without considerable effect on chronic pain and complications in patients undergoing thoracotomy.
开胸术后疼痛管理不当会导致严重并发症。已在胸椎旁神经阻滞(TPVB)中添加了几种佐剂以增强其效果。本研究旨在评估在TPVB中添加氯胺酮对开胸手术相关急性和慢性疼痛的影响。
这项随机对照双盲试验纳入了60例计划行开胸手术的患者。患者被随机分为两组:K组:接受TPVB + 1 mL氯胺酮(50 mg)。C组(n = 30):接受TPVB(19 mL 0.5%左旋布比卡因+ 1 mL生理盐水)作为对照组。
与对照组相比,K组在首次请求镇痛方面有显著延迟,在最初24小时和48小时所需吗啡较少,并且在各个时间点静息和深呼吸时的数字评分量表得分较低。然而,两组在开胸术后疼痛综合征以及2个月和3个月时的并发症发生率方面相当。
在TPVB中添加氯胺酮可产生更好的镇痛效果,表现为首次补救镇痛时间显著延迟、阿片类药物总消耗量降低以及疼痛评分降低,且对开胸手术患者的慢性疼痛和并发症没有显著影响。